AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29047413 — intervention group
Group type: EXPERIMENTAL
Intervention: VHA-guided transfusion therapy
Number of subjects: 392
Study 29047413 — intervention group
Group type: COMPARATOR
Intervention: CCT-guided transfusion therapy
Number of subjects: 392
Study 29047413 — intervention group
Group type: COMPARATOR
Intervention: CCT-guided therapy
Number of subjects: 392
Study 29047413 — intervention group
Group type: EXPERIMENTAL
Intervention: VHA-guided therapy
Number of subjects: 392
Study 29047413 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving patients
Number of subjects: 392
Study 25994664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 76
Study 25994664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23679679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 60
Study 23679679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23679679 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (nicotine satiation)
Number of subjects: 60
Study 21646441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin add-on therapy
Number of subjects: 0
Study 21646441 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20024757 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-related stigma (measured by Internalized Shame and Perceived Stigma)
Number of subjects: 408
Study 20024757 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional social support
Number of subjects: 408
Study 20024757 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized shame and emotional social support
Number of subjects: 408
Study 17536120 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (300 mg)
Number of subjects: 42
Study 17536120 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (150 mg twice daily for two weeks)
Number of subjects: 42
Study 17536120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17536120 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (acute treatment)
Number of subjects: 42
Study 17536120 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (two weeks treatment)
Number of subjects: 42
Study 15467101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr-pic) supplementation (924 ug Cr/d)
Number of subjects: 32
Study 15467101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15467101 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training (RT)
Number of subjects: 32
Study 15467101 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Cr-pic
Number of subjects: 32
Study 11426898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 53
Study 11426898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 53
Study 11426898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 11426898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg and 50 mg
Number of subjects: 53
Study 11120458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes management (IDM)
Number of subjects: 17
Study 11120458 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (0.25 mg/kg/day)
Number of subjects: 17
Study 9105164 — intervention group
Group type: EXPERIMENTAL
Intervention: C II treatment (chicken cartilage soup containing heat degenerated C II)
Number of subjects: 38
Study 8456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial mean minimal diameter of 74 coronary obstructions was 1.94 ± 0.09 mm; follow-up showed a reduction of 0.12 ± 0.04 mm (6%) in minimal diameter (p < 0.005).
Number of subjects: 26
Study 8456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial mean 'normal' reference diameter was 3.06 ± 0.11 mm.
Number of subjects: 26
Study 8456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a minimal change of 0.27 mm in arterial diameter as a categoric variable.
Number of subjects: 26
Study 8456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial severity of disease as a determinant of progression.
Number of subjects: 26
Study 8456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor in disease progression.
Number of subjects: 26
Study 2951824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 40 micrograms + fenoterol, 400 micrograms
Number of subjects: 2
Study 2951824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 0.5 mg + fenoterol, 2.0 mg
Number of subjects: 2
Study 2951824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31608144 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite pain patterns from L5 and S1 nerve roots
Number of subjects: 93
Study 31608144 — intervention group
Group type: COMPARATOR
Intervention: Composite pain patterns shown to clinicians
Number of subjects: 93
Study 31608144 — intervention group
Group type: COMPARATOR
Intervention: Use of composite pain drawings
Number of subjects: 93
Study 29869044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse representation-based variable selection (SRVS) for patient-specific genetic marker selection
Number of subjects: 851
Study 29869044 — intervention group
Group type: EXPERIMENTAL
Intervention: SRVS method
Number of subjects: 851
Study 27018896 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of depomedrol
Number of subjects: 50
Study 27018896 — intervention group
Group type: COMPARATOR
Intervention: BMP-2 with saline (control)
Number of subjects: 50
Study 25535146 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid
Number of subjects: 90
Study 25535146 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 90
Study 22459779 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral valve placement aiming for total occlusion of one lobe
Number of subjects: 22
Study 22459779 — intervention group
Group type: COMPARATOR
Intervention: Bilateral valve placement in two contralateral lobes with incomplete closure
Number of subjects: 22
Study 20201624 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based coaching, daily use of proprietary olfactive-based personal care products, and periodic feedback reports (Group 1)
Number of subjects: 562
Study 20201624 — intervention group
Group type: COMPARATOR
Intervention: Online coaching only (Group 2)
Number of subjects: 562
Study 20201624 — intervention group
Group type: COMPARATOR
Intervention: No active stress management program (Group 3)
Number of subjects: 562
Study 18398227 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH device
Number of subjects: 297
Study 18398227 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 297
Study 15812451 — intervention group
Group type: EXPERIMENTAL
Intervention: ECM plus unprotected powder enzymes
Number of subjects: 14
Study 15812451 — intervention group
Group type: COMPARATOR
Intervention: ECM alone
Number of subjects: 14
Study 12200654 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) indices
Number of subjects: 659
Study 12200654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff levels of QUS indices for osteoporosis diagnosis
Number of subjects: 659
Study 12200654 — intervention group
Group type: EXPERIMENTAL
Intervention: QUS indices
Number of subjects: 659
Study 10080400 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal antibody ATG for DGF
Number of subjects: 83
Study 10080400 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression (CI) for IGF
Number of subjects: 83
Study 8530600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone cyclodextrin (SLT; 2.5 mg, administered three times per day)
Number of subjects: 63
Study 8530600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone cyclodextrin (SLT; 5.0 mg, administered three times per day)
Number of subjects: 63
Study 8530600 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE; 200 mg, given once every 20 days by IM injections)
Number of subjects: 63
Study 8530600 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including SLT and TE)
Number of subjects: 63
Study 2009248 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 840
Study 31540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated or moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874
Study 31540791 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (36.25 Gy in five fractions over 1-2 weeks)
Number of subjects: 874
Study 28806532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate load (PHOS; liquid supplement containing 1200 mg of phosphorus)
Number of subjects: 17
Study 28806532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 17
Study 28806532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate load (PHOS)
Number of subjects: 17
Study 26475373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive face-to-face informational program alone
Number of subjects: 0
Study 26475373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive face-to-face informational program followed by an Internet-based booster
Number of subjects: 0
Study 26475373 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 24494282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy at specific points (Yaoyangguan, Mingmen, Zhiyang, Shenzhu, Dazhui, Yamen, Fengfu, Baihui, Neck‐Jiaji) given 6 times a week for 21 days.
Number of subjects: 70
Study 24494282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group clinical efficacy 96.77% (30/31), adverse reactions 6.45% (2/31).
Number of subjects: 70
Study 24494282 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 70
Study 21717781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Ashi‐point, Baihui (GV 20), Taiyang (EX‐HN 5), Shuaigu (GB 8), Fengchi (GB 20), Benshen (GB 13), Lieque (LU 7), needles retained for 30 min, once daily, 6 times a week for 4 weeks)
Number of subjects: 60
Study 21717781 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment (Flunarizine 10 mg, once every night for 4 weeks)
Number of subjects: 60
Study 19735405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AirwayScope
Number of subjects: 140
Study 19735405 — intervention group
Group type: COMPARATOR
Intervention: Glidescope
Number of subjects: 140
Study 18261355 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 37
Study 18261355 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 37
Study 18261355 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 37
Study 15207952 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 15245
Study 15207952 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15245
Study 11810777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (oral tamoxifen for five years; premenopausal patients received bilateral ovary ablation followed by tamoxifen for five years)
Number of subjects: 369
Study 11810777 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTX + MTX + 5‐Fu + VCR + DXM (CMFVP) or CTX + MTX + 5‐Fu (CMF))
Number of subjects: 369
Study 9569476 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (PRP-T)
Number of subjects: 262
Study 8049029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm collection in serum medium (SM)
Number of subjects: 16
Study 8049029 — intervention group
Group type: COMPARATOR
Intervention: Sperm collection in sterile cup (DRY)
Number of subjects: 16
Study 2567739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 12 mg acrivastine
Number of subjects: 6
Study 2567739 — intervention group
Group type: COMPARATOR
Intervention: Colonic administration of 12 mg acrivastine
Number of subjects: 6
Study 1099491 — intervention group
Group type: EXPERIMENTAL
Intervention: AN448 (active drug)
Number of subjects: 21
Study 1099491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study 30904834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg at the end of the surgical procedure and at day +1, n=611)
Number of subjects: 1222
Study 30904834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=611)
Number of subjects: 1222
Study 30904834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1222
Study 30904834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study 29135938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and Zeaxanthin supplementation
Number of subjects: 51
Study 29135938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25153411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest uNGAL tertile
Number of subjects: 473
Study 25153411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest urine NGAL-to-creatinine ratio (UNCR) tertile
Number of subjects: 473
Study 25153411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest urine NGAL-to-protein ratio (UNPR) tertile
Number of subjects: 473
Study 25153411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest UNPR tertile
Number of subjects: 473
Study 25153411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest UNCR tertile
Number of subjects: 473
Study 23783252 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 40
Study 23783252 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 40
Study 21784442 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg)
Number of subjects: 51
Study 21784442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 51
Study 19591334 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2/SHMP dentifrice
Number of subjects: 29
Study 19591334 — intervention group
Group type: COMPARATOR
Intervention: AlF3/Chx dentifrice
Number of subjects: 29
Study 16937132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic tooth brushing and oral hygiene instruction
Number of subjects: 23
Study 16937132 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (control group)
Number of subjects: 23
Study 12740960 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lateral cephalometric analysis
Number of subjects: 121
Study 12740960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier soft-tissue profile analysis
Number of subjects: 121
Study 12740960 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on 121 subjects
Number of subjects: 121
Study 10695908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in oxygen:nitrous oxide
Number of subjects: 75
Study 10695908 — intervention group
Group type: COMPARATOR
Intervention: Propofol/alfentanil
Number of subjects: 75
Study 10695908 — intervention group
Group type: COMPARATOR
Intervention: Propofol/remifentanil
Number of subjects: 75
Study 10695908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/nitrous oxide
Number of subjects: 75
Study 10695908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75
Study 9330783 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 50 micrograms/actuation
Number of subjects: 13
Study 9330783 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 100 micrograms/actuation
Number of subjects: 13
Study 9330783 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 200 micrograms/actuation
Number of subjects: 13
Study 8222650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinyl-estradiol (MERCILON)
Number of subjects: 49
Study 8222650 — intervention group
Group type: COMPARATOR
Intervention: 30 mcg ethinyl-estradiol (MARVELON)
Number of subjects: 49
Study 3512535 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 54
Study 3512535 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 54
Study 30919948 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine TAP block
Number of subjects: 200
Study 30919948 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal (IT) opioid administration with hydromorphone
Number of subjects: 200
Study 28474741 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Daclatasvir
Number of subjects: 20
Study 28474741 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 20
Study 25159700 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodCare (telephone-delivered cognitive behavioural therapy and risk-reduction programme)
Number of subjects: 121
Study 25159700 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 121
Study 23076706 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (three sessions per week, each lasting 60-90 min)
Number of subjects: 100
Study 23076706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 100
Study 22191012 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 20
Study 22191012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19427633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 12
Study 19427633 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 12
Study 16492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) added to lidocaine
Number of subjects: 30
Study 16492852 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (Control group)
Number of subjects: 30
Study 16422972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 16
Study 16422972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11731727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 18
Study 11731727 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 18
Study 11731727 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 9400091 — intervention group
Group type: EXPERIMENTAL
Intervention: Velten manipulation with mirror
Number of subjects: 231
Study 9400091 — intervention group
Group type: EXPERIMENTAL
Intervention: Music manipulation with mirror
Number of subjects: 231
Study 9400091 — intervention group
Group type: COMPARATOR
Intervention: Velten manipulation without mirror
Number of subjects: 231
Study 9400091 — intervention group
Group type: COMPARATOR
Intervention: Music manipulation without mirror
Number of subjects: 231
Study 9400091 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study 8434274 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and health education program during pregnancy (4-6 home visits by social workers)
Number of subjects: 2236
Study 8434274 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by social workers
Number of subjects: 2236
Study 3297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (150 mg quid)
Number of subjects: 16
Study 3297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 16
Study 3297265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 16
Study 3297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone or Disopyramide
Number of subjects: 16
Study 31724253 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1501D
Number of subjects: 114
Study 31724253 — intervention group
Group type: COMPARATOR
Intervention: US reference insulin glargine (US IG)
Number of subjects: 114
Study 31724253 — intervention group
Group type: COMPARATOR
Intervention: European reference insulin glargine (EU IG)
Number of subjects: 114
Study 30453494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistacia lentiscus (PL) supplement (2.8 g/day) for 3 months
Number of subjects: 60
Study 30453494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30453494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistacia lentiscus (PL) supplement
Number of subjects: 60
Study 28306134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular extension using a spring device with partial masticatory movements
Number of subjects: 25
Study 28306134 — intervention group
Group type: COMPARATOR
Intervention: Control procedure using a tongue depressor between incisor teeth
Number of subjects: 25
Study 26011955 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychological interventions including psychological support, relaxation training, and humanistic care based on conventional nursing care
Number of subjects: 100
Study 26011955 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 100
Study 22157664 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 0
Study 22157664 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study 20339911 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC) intervention
Number of subjects: 62
Study 20339911 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 62
Study 18539540 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux limb 150 cm, biliary limb 50 cm (Group 1)
Number of subjects: 105
Study 18539540 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux limb 250 cm, biliary limb 100 cm (Group 2)
Number of subjects: 105
Study 18539540 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 105